A recent large multi-centre study convincingly confirmed previous observations that the SYT-SSX1 fusion type, compared to SYT-SSX2, of synovial sarcoma is associated with a worse clinical outcome. Apart from the clinical impact, this fact also suggests (1) that the SYT-SSX fusion gene may influence molecular mechanisms involved in tumour growth and progression; and (2) that the SYT-SSX1 fusion type has a stronger influence on these mechanisms than SYT-SSX2. The nature of the underlying mechanisms is, however, still unknown. In this study we made use of the SYT-SSX1 vs SYT-SSX2 concept to investigate whether major, tumour relevant, and growth regulatory proteins (e.g. cyclins and cyclin-dependent kinases) may be involved. Using Western blotting analysis on 74 fresh, fusion variant-typed, tumour samples from localized synovial sarcoma, we found a significant correlation between SYT-SSX1 and high expression of cyclin A (P=0.003) and D1 (P=0.025). Our data suggest that SYT-SSX may influence the cell cycle machinery, and that the more aggressive phenotype of the SYT-SSX1 variant is due to an accelerated tumour cell proliferation.
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Keywords: cyclin A; cyclin D1; SYT-SSX; synovial sarcoma Synovial sarcoma constitutes a highly malignant soft tissue sarcoma and has the propensity to occur in the extremities of young and middle-aged adults (dos Santos et al., 2001; Ladanyi, 2001) . Cytogenetically, synovial sarcoma is characterized by the translocation t(X;18)(p11.2;q11.2) (Turc-Carel et al., 1987) resulting in a fusion between the SYT gene on chromosome 18 and SSX1, SSX2 or, rarely, SSX4 on the X chromosome and the formation of new chimeric genes, SYT-SSX1, SYT-SSX2 or SYT-SSX4 (Clark et al., 1994; de Leeuw et al., 1995; Skytting et al., 1999) .The function of these fusion genes is, however, still unclear. However, increasing evidence has implicated that SYT-SSX could play an important role in synovial sarcoma development and progression (Ladanyi, 2001) .
Several independent studies showed that SYT-SSX1, compared to SYT-SSX2, has a significantly unfavourable prognosis (Kawai et al., 1998; Nilsson et al., 1999; Inagaki et al., 2000) . These results were recently confirmed by a multi-institutional retrospective study on 243 cases of synovial sarcoma, in which the SYT-SSX1 fusion type was found to be the only independent significant factor for overall survival in patients with localized disease at diagnosis (Ladanyi et al., 2002) . Apart from the clinical impact of this study, it also suggests that SYT-SSX interferes with mechanisms involved in tumour growth and progression, as well as that SYT-SSX1 has a stronger positive influence on these mechanisms compared to SYT-SSX2.
Two previous independent studies demonstrated an association between SYT-SSX1 and an increased proliferation activity, as assessed by Ki67 Inagaki et al., 2000) . Even though these results are based on limited numbers of cases, the concept is intriguing and consistent with the general assumption that deregulated cellular growth is the most fundamental property for tumour development and progression (Evan and Vousden, 2001) . In a recent study we approached this issue by blocking the expression of SYT-SSX in cultured synovial sarcoma cells using antisense oligonucleotides. Our results showed that SYT-SSX was crucial for expression of cyclin D1. In fact, antisense oligonucleotides to SYT-SSX specifically destabilized cyclin D1 and subsequently inhibited the tumour cells growth (Xie et al., 2002) . These observations imply that the SYT-SSX fusion gene may play an important role in the cell cycle machinery, and based on them we have now undertaken a study on 74 fresh frozen samples of localized synovial sarcoma to investigate whether SYT-SSX1 and SYT-SSX2 fusion types may affect major, cancer relevant, cell cycle regulators differentially.
First we analysed different amounts of proteins (10 -90 mg) to determine the optimal amount of loaded protein. For this purpose cyclin D1 was measured. Cyclin D1 signals increased with the amount of loaded proteins ( Figure 1a , left panel), and the correlation was found to be linear (Figure 1a, right panel) . In the following analyses, 50 mg proteins from each sample were used for Western blotting.
Expression levels of cyclins (A, D1 and E), cyclindependent kinases (CDKs), p27 and the protooncogene protein Bcl-2 were quantitatively assessed in fresh-frozen tissues from all 74 cases by Western blotting (Figure 1b) . b-actin was used as a loading control. The intensities of the signals were quantified by scanning densitometry. All obtained data are presented in Table 1 . As shown in Figure 1b and Table 1 , the signal intensities of cyclin A, E and D1 and p27 showed the largest variations among the cases. well as p27 and BCL-2 were detected by Western blotting in 74 fresh-frozen synovial sarcoma samples. All samples were proven to be highly representative for synovial sarcoma tissue. The total protein of the tumour samples was extracted with a lysis buffer (50 mM TRIS-HCl pH 7.5, 150 mM NaCl, 1% NP-40 supplemented with protease inhibitor tablet) for 1 h on ice. After centrifugation at 1600 g for 5 min at 48C, the supernatants, containing the total protein, were assessed by dye-binding Bio-Rad protein assay for protein concentration. For all samples, the same amount of total protein (50 mg) was subjected to SDS -PAGE. The membranes were probed with: anti-cyclin D1 (M-20) (1 : 500), anti-cyclin E (HE-12) (1 : 500), anti-cyclin A (BF-683) (1 : 500), anti-CDK4 (H-22) (1 : 500), anti-CDK2 (M-2) (1 : 500), anti-p27 (1 : 500) and anti-BCL-2 (100) (1 : 500). All these antibodies were from Santa Cruz (CA). b-actin (1 : 500) was used as a loading control. The density of the bands was assessed using Multianalyst software SYT-SSX1 and cyclin A and D1 Y Xie et al To determine suitable 'cut offs' between low and high expression for the investigated proteins, we made distribution histograms regarding intensities for each of them. The distribution histograms for cyclins A and D1 are shown in Figure 2 . As can be seen, cyclin A exhibits a bimodal distribution and the cut off was set between the two peaks at baseline resolution level (Figure 2a ). This means that the cut off is set at a comparably insensitive level, and that limited adjustments of it would not affect the outcome of statistical analysis. From this it follows that 53 and 21 cases having a low and high cyclin A expression, respectively. The variation of cyclin D1 expression was also large but the distribution pattern differed considerably from that of cyclin A. There was a large and relative narrow peak with no or very weak expression (OD 0 -0.4) representing the majority of cases (54 cases), followed by a very broad 'peak' with higher expression (OD 0.5 -2.8) representing the remaining 20 cases (Figure 2b ). The cut off was therefore set between these peaks at OD 0.4 -0.5, which is also a quite insensitive level. In a corresponding manner, using the distribution curves, we could identify suitable cut off levels with base line resolutions for the other proteins investigated. These were for cyclin E, p27, Bcl-2, CDK4 and CDK2; 1.0 (range 0 -4.1), 0.4 (range 0 -0.9), 3.7 (range 0.1 -7.0), 3.5 (range 0.2 -8.3) and 1.4 (range 0.1 -3.2), respectively.
Using RT -PCR and sequence analysis it was found that 40 and 34 cases expressed SYT-SSX1 and SYT-SSX2, respectively (Table 1) . No atypical transcripts were encountered in these cases. Applying the above cut off values, we analysed the correlation between high expression of each cell cycle regulatory protein and SYT-SSX fusion type. Statistical analysis showed that a high level of either cyclin A or D1 was significantly associated with the SYT-SSX1 fusion type. In the SYT-SSX1 group, 17 cases expressed a high level of cyclin A, compared to only four cases of high cyclin A in the SYT-SSX2 group (P=0.003) (Figure 3a) . Even if we used the mean value of cyclin A expression (1.02) as cut off, the correlation was still significant (P=0.007) (see Table 1 ). For cyclin D1, 15 cases with high level of cyclin D1 was located in the SYT-SSX1 group, compared to only five cases in the SYT-SSX2 group (P=0.025) (Figure 3b ). Even if we used the median value as cut off, there was still a significant correlation between SYT-SSX1 and high cyclin D1.
In contrast to cyclin A and cyclin D1, no significant correlations were found between the expressions of Bcl-2, cyclin E, CDK2, CDK4, p27 and SYT-SSX fusion type. Even when we changed the cut off levels, none of them exhibited any significant association to the fusion variants (data not shown).
We also calculated the mean values+standard error of means (mean+s.e.m.) of cyclin A and D1 expression, using the O.D. values (Table 1) , for all 40 SYT-SSX1 and 34 SYT-SSX2 cases (see Table 1 ). Herewith the mean+s.e.m. of cyclin A expression was 1.26+0.14 and 0.74+0.10 in the SYT-SSX1 and SYT-SSX2 cases (P=0.0005), respectively. The corresponding values for cyclin D1 were 0.59+0.11 and 0.34+0.11 (P=0.01). These data provide further support for a link between SYT-SSX1 and cyclin A a Types of SYT-SSX fusion were determined by RT -PCR and sequence analysis as previously described . Expression levels of the proteins were assessed by Western blotting and densitometry and D1. In contrast, there was no significant correlation between SYT-SSX1 and mean expression of any of the other proteins. Cyclin D1 is accumulated in mid-G1 phase, and over expression of it has been reported to shorten the G1 phase and cause more rapid entry into S phase (Quelle et al., 1993) . Cyclin A is essentially expressed in the S phase, in which DNA replication occurs, but is also involved in the G2-M phase transition (Sherr, 1996) . Over expression of cyclin A or D1 has been demonstrated to be associated with tumour progression and/or poor prognosis in a variety of human malignancies, including soft tissue sarcomas, breast, esophageal, pancreatic and colorectal carcinomas (Kim et al., 1998; Shamma et al., 1998; Handa et al., 1999; Huuhtanen et al., 1999; Bukholm et al., 2001) .
Since the cyclinA/CDK2 complex is required for DNA replication during S phase and initiation of mitosis, the expression level of cyclin A is usually closely linked to the proliferation indices (Bukholm et al., 2001; Handa et al., 1999; Huuhtanen et al., 1999) . This fact taken together with our finding that cyclin A is higher expressed in SYT-SSX1 cases, suggests that the tumour cells of this fusion type harbour a higher proliferative activity compared to the SYT-SSX2 cells.
This would also be consistent with the observations that the SYT-SSX1 cases exhibited comparatively faster onset of metastatic disease (Kawai et al., 1998; Nilsson et al., 1999) .
Cyclin D1, which is synthesized and assembled with either CDK 4 or CDK 6 in early and mid-G1 phase, is the major driving event in the transition from the G1 to S phase of the cell cycle (Sherr, 1995) . Therefore, the increased expression of cyclin D1 in the SYT-SSX1 tumours may reflect an increased transfer of cells from G1 to S. Actually, most of the cases with an high level of cyclin D1 also exhibited an increased expression of cyclin A (see Table 1 ).
Bcl-2, which belongs to a family of key regulators for protection of tumour cell apoptosis (Adams and Cory, 1998), was first found in human follicular lymphoma with the translocation t(14; 18)(q32; p21), juxtaposing the IgH-joining region with Bcl-2 gene from 18q21 and thereby constitutively activating the Bcl-2 expression. In line with a study by Mancuso et al. (2000) , we found that the expression of Bcl-2 was strongly expressed in the majority of synovial sarcomas. This event may be important for the malignant phenotype of synovial sarcoma. However, we can conclude that the Bcl-2 expression level is independent of SYT-SSX fusion type.
Some studies have shown that over expression of cyclin E is associated with unfavourable prognosis in certain types of tumours (Mishina et al., 2000; Nielsen et al., 1996) . We could, however, not find any correlation between cyclin E and the two fusion types.
P27 is a key inhibitor in cell cycle regulation and belongs to the CIP1/KIP1 family. P27 is able to inhibit several cyclin/CDKs, whose degradation is required for G1 to S phase transition (Hunter and Pines, 1994; Sherr, 2000) . Consistently, we found that p27 expression was comparatively weak in the synovial sarcoma samples. This profile would favour the malignant growth of this tumour type. However, similar to the case with Bcl-2 and cyclin E we did not find any link between p27 and the SYT-SSX fusion types.
So far the exact function of the fusion protein and wild type SYT and SSX proteins is not clear. The Cterminal of SYT protein is rich in the glutamine, proline, glycine and tyrosine residues and seems to be involved in transcriptional activity. In contrast, SSX possesses a repressor domain located in the C-terminus, which is retained in the fusion protein (Thaete et al., 1999) . Thus, the SYT-SSX fusion protein contains both potential transcriptional and repressor domains. Even though SYT-SSX1 and SYT-SSX2 show high homology, 13 amino acids differ in the SSX-part (de Leeuw et al., 1995) . Seemingly, this difference may be enough to alter the functional capacity of the SYT-SSX1 and SYT-SSX2 proteins.
Taken together, our present results, demonstrating a link between fusion types and cyclin A and D1, provide further support to the notion that SYT-SSX influences the cell cycle machinery, as well as this influence may be differential with regard to type of SYT-SSX fusion. Figure 3 The association between high or low expression of cyclin A (a) or cyclin D1 (b) and SYT-SSX1 or SYT-SSX2. Statistical analysis was performed using the w 2 -test, P values less than 0.05 was considered as statistically significant SYT-SSX1 and cyclin A and D1 Y Xie et al
